预约演示

Nkarta's blood cancer CAR stalls again, with falling response rate forcing it out of the race

2024-03-22

细胞疗法免疫疗法临床研究

William Blair analysts said they view the pipeline reprioritization “positively.”

Nkarta’s CAR NK blood cancer candidate has again stalled after making a speedy start. The response rate fell away sharply in the latest update, mirroring what happened in an earlier cohort and driving the cell therapy developer to mothball the program.

The off-tCAR NK blood cancer NKX101, consists of CAR NK cells engineered to express a NKG2D receptor. Through the engineering, Nkarta tried to boost the longevity, potency and activity of NK cells and create a cell therapy that is effective in a range of blood cancers and solid tumors. The drug candidate has failed to live up to those ambitions, despite twice showing promise in small numbers of patients.

Nkarta reported four completeNKX101nses in six acute myeloid leukemia (AML) last year,NKG2D receptort to push ahead. Yet, the next 14 patients only included one complete response. The crumbling response rate, which fell from 67% to 25%, has prompted Nkartblood cancerstize solid tumors

The biotech is yet to completely give up on theacute myeloid leukemia (AML)gs saying in a statement that the team will “evaluate options for optimizing future study design, dosing schedule and manufacturing.” But Nkarta sees its autoimmune candidate as a better use of the NKX101 million it had at the end of last year. The biotech still expects its cash to last into 2026, a runway made possible by layoffs last year.

William Blair analysts said they view the pipeline reprioritization “positively” in a research note, telling inventors that they believe the shift “accurately reflects increased investor enthusiasm for the potential of allogeneic cell therapies for autoimmune diseases and waning interest in NKX101, particularly in light of the disappointing efficacy in AML.”

The falling response rate echoes what happened in an earlier cohort. In 2022, Nkarta said that three of the first five AML patients to receive the highest doses of NKX101 had complete responses and raised $230 million on the back of the news. Howeveautoimmune diseases saw one more complete rNKX101e in the next 13 high-dose patients.AML

Nkarta responded to the first collapse of its response rate by switching its focus to a cohort that received a differenAMLonditioning regimen. We now know the 67% rNKX101e rate seen in that cohort was another mirage, not a sign that Nkarta had cracked the CAR NK puzzle by giving cytarabine, a chemotherapy drug, before the cell therapy.

The failure to find a path forward for the cancer candidate leaves Nkarta’s hopes resting on NKX019, the CD19-directed CAR NK prospect that the FDA cleared for testing in lupus nephritis last year. Developers of CD19 cell therapies have surged into lupus over the past 18 months, cytarabineby data that suggest the treatments may cure the autoimmune disease.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构